UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 25

Sortiert nach

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects

Antimicrobial agents and chemotherapy, 2016-10, Vol.60 (10), p.6326-6332

2016

Volltextzugriff (PDF)

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects

Antimicrobial agents and chemotherapy, 2018-04, Vol.62 (4)

2018

Volltextzugriff (PDF)

Levofloxacin Inhalation Solution (MP-376) in Patients with Cystic Fibrosis with Pseudomonas aeruginosa

American journal of respiratory and critical care medicine, 2011-06, Vol.183 (11), p.1510-1516

2011

Volltextzugriff (PDF)

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Biapenem in Healthy Adult Subjects

Antimicrobial agents and chemotherapy, 2021-04, Vol.65 (5)

2021

Volltextzugriff (PDF)

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment

Antimicrobial agents and chemotherapy, 2018-03, Vol.62 (3)

2018

Volltextzugriff (PDF)

A phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the pharmacokinetics, safety, and tolerability of oral ceftibuten in healthy adult subjects

Antimicrobial agents and chemotherapy, 2024-01, Vol.68 (1), p.e0109923-e0109923

2024

Volltextzugriff (PDF)

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients

Journal of cystic fibrosis, 2016-07, Vol.15 (4), p.495-502

2016

Volltextzugriff (PDF)

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients

Journal of cystic fibrosis, 2015-07, Vol.14 (4), p.507-514

2015

Volltextzugriff (PDF)

Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects

Diagnostic microbiology and infectious disease, 2004-10, Vol.50 (2), p.95-102

2004

Volltextzugriff (PDF)

Pneumocephalus Due to Invasive Fungal Sinusitis

Clinical infectious diseases, 2000-01, Vol.30 (1), p.215-217

2000

Volltextzugriff (PDF)

The Agent of Bacillary Angiomatosis: An Approach to the Identification of Uncultured Pathogens

The New England journal of medicine, 1990-12, Vol.323 (23), p.1573-1580

1990

Volltextzugriff (PDF)

1387. Phase I Study to Evaluate the Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Doses (SAD/MAD) of Intravenous (IV) Minocycline in Healthy Adult Subjects

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S425-S426

2018

Volltextzugriff (PDF)

Bartonella infections

Current clinical topics in infectious diseases, 1997, Vol.17, p.269

Loutit, J S

1997

Volltextzugriff (PDF)

Lemierre's syndrome

Southern medical journal (Birmingham, Ala.), 1997-06, Vol.90 (6), p.640-643

1997

Volltextzugriff (PDF)

Bartonella Infections: Diverse and Elusive

Hospital Practice, 1998-12, Vol.33 (12), p.37-49

Loutit, Jeffery S.

1998

Volltextzugriff (PDF)

The Agent of Bacillary Angiomatosis

The New England journal of medicine, 1991-05, Vol.324 (21), p.1511-1513

1991

Volltextzugriff (PDF)

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Infectious diseases and therapy, 2018-12, Vol.7 (4), p.439-455

2018

Volltextzugriff (PDF)

QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics

Frontiers in microbiology, 2021-07, Vol.12, p.697180-697180

2021

Volltextzugriff (PDF)

In Vitro Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa

Antimicrobial agents and chemotherapy, 2021-05, Vol.65 (6)

2021

Volltextzugriff (PDF)

In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales

Antimicrobial agents and chemotherapy, 2023-11, Vol.67 (11), p.e0044023-e0044023

2023

Volltextzugriff (PDF)

Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam

Antimicrobial agents and chemotherapy, 2018-10, Vol.62 (10)

2018

Volltextzugriff (PDF)

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

Journal of cystic fibrosis, 2016-09, Vol.15 (5), p.634-640

2016

Volltextzugriff (PDF)

Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory

Antimicrobial agents and chemotherapy, 2017-02, Vol.61 (2)

2017

Volltextzugriff (PDF)

Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials

Open forum infectious diseases, 2017-03, Vol.4 (2), p.ofx063-ofx063

2017

Volltextzugriff (PDF)

Cerebral Sparganosis: Case Report and Review

Reviews of infectious diseases, 1991-01, Vol.13 (1), p.155-159

1991

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Humans
(15)
Microbiology
(15)
Adult
(12)
Male
(11)
Female
(9)
Pharmacology & Pharmacy
(9)
Infectious Diseases
(7)
Antibiotics
(6)
Biological And Medical Sciences
(6)
Medical Sciences
(6)
Anti-Bacterial Agents - Administration & Dosage
(5)
General & Internal Medicine
(5)
Pharmacokinetics
(5)
Pharmacology
(5)
Administration, Inhalation
(4)
Anti-Bacterial Agents
(4)
Boronic Acids
(4)
Cystic Fibrosis
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects

Levofloxacin Inhalation Solution (MP-376) in Patients with Cystic Fibrosis with Pseudomonas aeruginosa

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Biapenem in Healthy Adult Subjects

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment

A phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the pharmacokinetics, safety, and tolerability of oral ceftibuten in healthy adult subjects

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients

Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects

Pneumocephalus Due to Invasive Fungal Sinusitis

The Agent of Bacillary Angiomatosis: An Approach to the Identification of Uncultured Pathogens

1387. Phase I Study to Evaluate the Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Doses (SAD/MAD) of Intravenous (IV) Minocycline in Healthy Adult Subjects

Bartonella infections

Lemierre's syndrome

Bartonella Infections: Diverse and Elusive

The Agent of Bacillary Angiomatosis

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics

In Vitro Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa

In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales

Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory

Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials

Cerebral Sparganosis: Case Report and Review

Suchergebnisse filtern